Paediatric indication for Xalatan

Pfizer has received a licence extension for Xalatan 0.005% (latanoprost) permitting use of the eye drops in children with elevated intraocular pressure or glaucoma. Dosing is the same as for adults.

Latanoprost is the first prostaglandin analogue to complete safety and efficacy trials in the paediatric population and to be indicated for use in patients under 18 years old in the UK. No data are available for preterm infants (<36 weeks gestational age) and data are very limited in children under 1 year.

View Xalatan drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases